HC Wainwright reissued their buy rating on shares of KalVista Pharmaceuticals (NASDAQ:KALV – Get Rating) in a research report report published on Friday morning, Benzinga reports. HC Wainwright currently has a $16.00 price objective on the specialty pharmaceutical company’s stock.
KALV has been the topic of several other reports. SVB Leerink lowered their target price on KalVista Pharmaceuticals from $30.00 to $20.00 and set an outperform rating on the stock in a report on Friday, February 3rd. Needham & Company LLC restated a buy rating and issued a $22.00 price objective (down previously from $24.00) on shares of KalVista Pharmaceuticals in a research note on Thursday, March 9th.
KalVista Pharmaceuticals Price Performance
Shares of KALV stock opened at $7.49 on Friday. The business has a fifty day moving average of $7.55 and a 200 day moving average of $8.00. The firm has a market capitalization of $184.40 million, a price-to-earnings ratio of -2.10 and a beta of 1.12. KalVista Pharmaceuticals has a 1 year low of $4.12 and a 1 year high of $17.06.
Insider Transactions at KalVista Pharmaceuticals
Institutional Trading of KalVista Pharmaceuticals
A number of hedge funds have recently bought and sold shares of the stock. JPMorgan Chase & Co. grew its position in shares of KalVista Pharmaceuticals by 24.9% during the 1st quarter. JPMorgan Chase & Co. now owns 13,424 shares of the specialty pharmaceutical company’s stock worth $198,000 after buying an additional 2,677 shares during the period. Bank of New York Mellon Corp increased its holdings in KalVista Pharmaceuticals by 5.8% during the first quarter. Bank of New York Mellon Corp now owns 69,570 shares of the specialty pharmaceutical company’s stock worth $1,026,000 after buying an additional 3,838 shares during the last quarter. MetLife Investment Management LLC increased its holdings in shares of KalVista Pharmaceuticals by 103.8% in the first quarter. MetLife Investment Management LLC now owns 12,495 shares of the specialty pharmaceutical company’s stock valued at $184,000 after purchasing an additional 6,365 shares during the last quarter. Rhumbline Advisers increased its holdings in shares of KalVista Pharmaceuticals by 16.3% in the first quarter. Rhumbline Advisers now owns 22,150 shares of the specialty pharmaceutical company’s stock valued at $326,000 after purchasing an additional 3,100 shares during the last quarter. Finally, BlackRock Inc. boosted its position in shares of KalVista Pharmaceuticals by 2.6% in the first quarter. BlackRock Inc. now owns 1,544,027 shares of the specialty pharmaceutical company’s stock valued at $22,757,000 after acquiring an additional 39,407 shares during the period.
KalVista Pharmaceuticals Company Profile
KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.
- Get a free copy of the StockNews.com research report on KalVista Pharmaceuticals (KALV)
- First Republic: First Rate Risk or Time To Buy?
- These Hedge Funds Are Getting Crushed By SVB
- Buy The Dip In The Charles Schwab Corporation
- ZIM Integrated Shipping Services: Up 15% But Don’t Chase It
- FedEx Is A Buy Going Into Earnings
Receive News & Ratings for KalVista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KalVista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.